Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
Patients can now get the starting 2.5 mg dose for $299 per month
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Enabling a new era in minimally invasive obesity treatment across Europe
Subscribe To Our Newsletter & Stay Updated
